Literature DB >> 9002189

The structures of oligosaccharides isolated from the lipopolysaccharide of Moraxella catarrhalis serotype B, strain CCUG 3292.

P Edebrink1, P E Jansson, G Widmalm, T Holme, M Rahman.   

Abstract

The oligosaccharides from the lipopolysaccharides of Moraxella catarrhalis serotype B, strain CCUG 3292, were isolated after mild acid hydrolysis and separated by high-performance anion-exchange chromatography. The structures of the oligosaccharides were established by fast atom bombardment mass spectrometry and nuclear magnetic resonance spectroscopy. It is concluded that the oligosaccharides comprise a mixture of mainly a nona- and a deca-saccharide. [formula: see text] Smaller amounts of undeca-saccharides and of truncated forms, namely, hexa-, hepta-, and octa-saccharides, were also detected.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9002189     DOI： 10.1016/s0008-6215(96)90132-9

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN： 0008-6215            Impact factor:   2.104


  15 in total

1.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading.

Authors:  Andrew D Cox; Frank St Michael; Dhamodharan Neelamegan; Suzanne Lacelle; Chantelle M Cairns; Marzia M Giuliani; Alessia Biolchi; J Claire Hoe; E Richard Moxon; James C Richards
Journal:  Glycoconj J       Date:  2010-10-05       Impact factor: 2.916

2.  Multiplex PCR assay that identifies the major lipooligosaccharide serotype expressed by Moraxella catarrhalis clinical isolates.

Authors:  Katie J Edwards; Johanna M Schwingel; Anup K Datta; Anthony A Campagnari
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly.

Authors:  Katie J Edwards; Simon Allen; Bradford W Gibson; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.

Authors:  Dabin Ren; Shengqing Yu; Song Gao; Daxin Peng; Ronald S Petralia; Artur Muszynski; Russell W Carlson; John B Robbins; Chao-Ming Tsai; David J Lim; Xin-Xing Gu
Journal:  Vaccine       Date:  2011-04-16       Impact factor: 3.641

8.  Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of moraxella catarrhalis is a factor in resistance to bactericidal activity mediated by normal human serum.

Authors:  A Zaleski; N K Scheffler; P Densen; F K Lee; A A Campagnari; B W Gibson; M A Apicella
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies.

Authors:  Johanna M Schwingel; Katie J Edwards; Andrew D Cox; Hussein Masoud; James C Richards; Frank St Michael; Carmen D Tekwe; Sanjay Sethi; Timothy F Murphy; Anthony A Campagnari
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

10.  Characterization of a trifunctional glucosyltransferase essential for Moraxella catarrhalis lipooligosaccharide assembly.

Authors:  Nicole R Luke-Marshall; Katie J Edwards; Shauna Sauberan; Frank St Michael; Evgeny V Vinogradov; Andrew D Cox; Anthony A Campagnari
Journal:  Glycobiology       Date:  2013-05-29       Impact factor: 4.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.